BR112015016647A2 - processo para a preparação de um derivado de fluorlactona - Google Patents

processo para a preparação de um derivado de fluorlactona

Info

Publication number
BR112015016647A2
BR112015016647A2 BR112015016647A BR112015016647A BR112015016647A2 BR 112015016647 A2 BR112015016647 A2 BR 112015016647A2 BR 112015016647 A BR112015016647 A BR 112015016647A BR 112015016647 A BR112015016647 A BR 112015016647A BR 112015016647 A2 BR112015016647 A2 BR 112015016647A2
Authority
BR
Brazil
Prior art keywords
derivative
preparation
fluorlactone
formula
fluorlactones
Prior art date
Application number
BR112015016647A
Other languages
English (en)
Inventor
Zhu Guoliang
Zheng Jianbing
Zhao Jianqiang
Chen Rongmin
Li Yuanqiang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112015016647A2 publication Critical patent/BR112015016647A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/26—Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

1/1 resumo processo para a preparação de um derivado de fluorlactona descreve-se um novo processo para a preparação de um derivado da fórmula o o ho ch i 3 ho f , e de seu derivado acilado da fórmula 1 o r o o ch v 3 1 ro f . em que r1 representa um grupo de proteção hidroxila. as fluorlactonas aciladas da fórmula v, com particularidade o derivado de benzoila com r1 =benzil são precursores importantes para a síntese de compostos pró- fármacos que são dotados do potencial para serem inibidores potentes do vírus da hepatite c (vhc) polimerase ns5b.
BR112015016647A 2013-01-14 2014-01-13 processo para a preparação de um derivado de fluorlactona BR112015016647A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2013070413 2013-01-14
PCT/EP2014/050439 WO2014108525A1 (en) 2013-01-14 2014-01-13 Process for the preparation of a fluorolacton derivative

Publications (1)

Publication Number Publication Date
BR112015016647A2 true BR112015016647A2 (pt) 2017-07-11

Family

ID=49989697

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015016647A BR112015016647A2 (pt) 2013-01-14 2014-01-13 processo para a preparação de um derivado de fluorlactona

Country Status (15)

Country Link
US (2) US9624183B2 (pt)
EP (1) EP2943475B1 (pt)
JP (1) JP6317367B2 (pt)
KR (2) KR102187280B1 (pt)
AR (1) AR094466A1 (pt)
BR (1) BR112015016647A2 (pt)
CA (1) CA2896253C (pt)
ES (1) ES2655851T3 (pt)
HK (2) HK1215020A1 (pt)
IL (1) IL239697A (pt)
MX (1) MX2015008661A (pt)
PT (1) PT2943475T (pt)
RU (1) RU2656600C2 (pt)
SG (1) SG11201505455VA (pt)
WO (1) WO2014108525A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3521297B1 (en) 2003-05-30 2021-12-22 Gilead Pharmasset LLC Modified fluorinated nucleoside analogues
AR094466A1 (es) 2013-01-14 2015-08-05 Hoffmann La Roche Proceso para la obtención de un derivado de fluorlactona
CN105111169A (zh) * 2015-07-08 2015-12-02 重庆沃肯精细化工有限公司 一种索菲布韦关键中间体的简便制备方法
CN109843860A (zh) 2016-08-16 2019-06-04 上海泓博智源医药股份有限公司 制备内酯衍生物及其中间体的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1957510A1 (en) 2005-12-09 2008-08-20 F.Hoffmann-La Roche Ag Antiviral nucleosides
AU2007336365B2 (en) * 2006-12-18 2013-03-07 F. Hoffmann-La Roche Ag Process for preparing 3,5-di-Omicron-acyl-2-fluoro-2-C-methyl-D-ribono-gamma-lactone
WO2008090046A1 (en) * 2007-01-23 2008-07-31 F. Hoffmann-La Roche Ag Alternate process for preparing 3,5-di-omicron-acyl-2-fluoro-2-c-methyl-d-ribono-gamma-lactone
AR094466A1 (es) 2013-01-14 2015-08-05 Hoffmann La Roche Proceso para la obtención de un derivado de fluorlactona

Also Published As

Publication number Publication date
HK1215020A1 (zh) 2016-08-12
US20170183317A1 (en) 2017-06-29
CA2896253A1 (en) 2014-07-17
HK1219094A1 (zh) 2017-03-24
US9624183B2 (en) 2017-04-18
KR102187280B1 (ko) 2020-12-07
RU2015130337A (ru) 2017-02-20
CA2896253C (en) 2021-01-12
JP2016508154A (ja) 2016-03-17
JP6317367B2 (ja) 2018-04-25
PT2943475T (pt) 2018-01-17
MX2015008661A (es) 2015-10-05
KR20150104205A (ko) 2015-09-14
IL239697A (en) 2017-12-31
US9845299B2 (en) 2017-12-19
WO2014108525A1 (en) 2014-07-17
US20150315165A1 (en) 2015-11-05
EP2943475A1 (en) 2015-11-18
AR094466A1 (es) 2015-08-05
RU2656600C2 (ru) 2018-06-06
ES2655851T3 (es) 2018-02-21
IL239697A0 (en) 2015-08-31
SG11201505455VA (en) 2015-08-28
EP2943475B1 (en) 2017-10-25
KR20200138424A (ko) 2020-12-09

Similar Documents

Publication Publication Date Title
DOP2016000069A (es) Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih
CY1119015T1 (el) 4'-αζιδο-3'φθορο υποκατεστημενα νουκλεοζιδιου παραγωγα ως αναστολεις αντιγραφης hcv rna
PE20151423A1 (es) Derivados tetrahidropiranilo inhibidores del hcv
CR20140238A (es) Derivados nucleósidos con sustitución 2´, 4´- difluoro-2´-metilo como inhibidores de la replicación del arn del vhc
CO6561788A2 (es) Inhibidores del virus de la hepatitis c
BR112015004113A2 (pt) 6-aminoácido heteroarila diidropirimidinas para o tratamento e profilaxia da infecção pelo vírus da hepatite b
ECSP15002066A (es) Inhibidores de virus de hepatitis c
BR112012017402A2 (pt) inibidores de vírus de flaviviridae
BR112014010576B8 (pt) compostos inibidores de neprilisina (nep), seus usos, processo de preparação dos compostos e composição farmacêutica compreendendo os compostos
BR112013031405A2 (pt) piridopirazinas substituídas como novos inibidores de syk
BRPI1009333B8 (pt) compostos inibidores de beta-secretase, seus usos, bem como composição farmacêutica
DOP2019000087A (es) Compuestos químicos
BR112012017382A2 (pt) compostos inibidores de viroses flaviviridae, uso dos mesmos e composição farmacêutica
CL2015002520A1 (es) Compuestos novedosos de pirimidina y piridina y su uso.
ECSP10010271A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
CO6361922A2 (es) Inhibidores del virus de la hepatitis c
UY32759A (es) Inhibidores del virus de la hepatitis c
BR112014018959A8 (pt) Compostos, composições farmacêuticas, utilizações de um composto e métodos para o tratamento do câncer
BR112015008037A2 (pt) compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção
BR112015016325A2 (pt) Composto, composição farmacêutica, e, usos de uma composição, composto, pró-droga ou sal farmaceuticamente aceitável do mesmo
BR112017018305A2 (pt) desacetoxitubulisina h e análogos da mesma
AR077080A1 (es) Compuestos de 2,3-dihidro-1h-indeno
CO2018010787A2 (es) Compuesto de griseofulvina
BR112014028692A2 (pt) processo para a preparação de compostos de 2-deoxi-2- fluoro-2-metil-d-ribofuranosil nucleosídeo
BR112014018636A8 (pt) Derivados de benzil sulfonamida úteis como inibidores de mogat-2

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: GILEAD PHARMASSET LLC (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 263/26 , C07D 307/33 , C07D 413/06

Ipc: C07D 263/26 (2006.01), C07D 307/33 (2006.01), C07D

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements